AstraZeneca on Thursday cemented its lead in bringing a preventative COVID-19 shot for the non-infected to market for people who do not respond well to vaccines, saying its antibody drug cocktail offered 83 per cent protection over six months.
The therapy, called AZD7442 or Evusheld, had previously been shown to confer 77 per cent protection against symptomatic illness after three months, in an earlier readout of the late-stage PROVENT trial in August.
The Anglo-Swedish company also said a separate study in patients with mild-to-moderate COVID-19 showed a higher dose of AZD7442 cut the risk of symptoms worsening by 88 per cent when given within three days of first symptoms.
The treatment is given in one go, as two sequential shots in the arm.
The latest results from the longer-term follow-ups potentially position AstraZeneca, like rival Pfizer as a future supplier of both COVID-19 vaccines and treatments, with AstraZeneca having said the therapy’s “real advantage” was as a preventative shot.
Pfizer has presented promising efficacy data on its oral COVID-19 treatment candidate, which can be more easily distributed than injections, and is also a leading vaccine supplier with partner BioNTech.
“These new data add to the growing body of evidence supporting AZD7442’s potential … We are progressing regulatory filings around the world and look forward to providing an important new option against SARS-CoV-2 as quickly as possible,” AstraZeneca Executive Vice President Mene Pangalos said in a statement, referring to the coronavirus that causes COVID-19.
The group last month sought approval for the medicine from U.S. and European authorities. Monoclonal antibodies from Regeneron, Lilly and GSK-Vir have been approved by U.S. regulators for treating unhospitalised COVID-19 patients.
Comments